Cooperative Agreement UG3CA290300
Award Date 7/5/24
Completion Date 5/31/26
Dollars Obligated $2.4M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- Federal Grant Award Summary Albert Einstein College of Medicine received a $680,121 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. This award supports fundamental research to understand the immunoevasion mechanisms employed by precancerous stem cells in basal-like breast cancer (BLBC), with the goal of developing immunoprevention strategies to intercept progression to aggressive...
- Federal Cooperative Agreement Summary New York University School of Medicine received a $703,423 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective September 1, 2025 through August 31, 2030. This prospective study examines circulating autoantibodies (AAbs) as biomarkers for breast cancer risk within the NYU Women's Health Study, a cohort of 14,274 women enrolled between 1985 and 1991. The research...
- This National Institutes of Health National Cancer Institute Project Grant of $470,532 provides funding from July 1, 2022 to June 30, 2027 to Brigham and Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to characterize immunometabolic pathways enabled by PARP inhibition in breast cancer. The grant aims to (1) define the mechanisms by which PARP inhibitors induce lipogenic tumor-associated macrophage development, (2) determine how lipogenic macrophages suppress...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...
- Federal Grant Award Summary Immunogenik, Inc. received a $398,997 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on June 9, 2025, with completion targeted for May 31, 2027. The company is developing a clinical-grade humanized antibody (hu-ALAIR1) that targets Leukocyte-Associated Immunoglobulin-Like Receptor 1 (LAIR1/CD305), a novel immune checkpoint expressed on tumor-associated macrophages. The therapeutic approach aims to...
- The National Cancer Institute (NCI) awarded a $605,314 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the efficacy of g-tocotrienol for preventing post-partum breast cancer. The grant is intended to support a 5-year research project starting on May 1, 2025 and ending on April 30, 2030. The project aims to leverage mouse models with different mitochondrial genomes to understand how...
- This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $151,040 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective January 16, 2026, with completion targeted for July 31, 2028. This award supports a research training and development initiative focused on investigating the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion in triple negative breast cancer (TNBC). The project comprises two primary...
- This federal Project Grant award of $378,444, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), will support research by Trustees of Indiana University, Indianapolis to investigate the role of Heat Shock Factor 1 (HSF1) in regulating immune cell infiltration into metastatic breast tumors. The goal is to determine how HSF1 activity impacts the recruitment of CD8+ T cells and other anti-tumor immune cells to metastatic breast cancer, with the...